INVITAE: Genetics from downstream to mainstream U B S G L O B A L H E A LT H C A R E C O N F E R E N C E
|
|
- Nelson Gordon
- 6 years ago
- Views:
Transcription
1 INVITAE: Genetics from downstream to mainstream U B S G L O B A L H E A LT H C A R E C O N F E R E N C E
2 Safe harbor statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's expectations regarding full-year 2017 revenue; the company s belief that it is winning the race to scale in its industry and opening up access for patients to address a wide spectrum of health issues, which is leading to increased utilization of its expanding platform; that being in-network with a majority of major payers and the rise in demand for its services in the first quarter will lead to significant revenue grow throughout the remainder of 2017; that additional payer contracts will be executed during the remainder of 2017; that exome testing can help clinicians make or confirm a diagnosis and develop an appropriate medical management plan; and that research continues to point to the broader utility of genetic information and precision of the company s services. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company's history of losses; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the company's ability to develop and commercialize new tests and expand into new markets; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the company's inability to raise additional capital on acceptable terms; risks associated with the company's ability to use rapidly changing genetic data to interpret test results accurately, consistently, and quickly; risks associated with the company's limited experience with respect to acquisitions; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the year ended December 31, These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements. NOTE: Invitae and the Invitae logo are trademarks of Invitae Corporation. All other trademarks and service marks are the property of their respective owners. Invitae Corporation. All Rights Reserved. 2
3 Invitae is a dynamic, rapidly growing company that is unlocking the power of genetics to change healthcare for the better Invitae Corporation. All Rights Reserved. 3
4 Genetics: real progress is catching up with the exuberance Invitae Corporation. All Rights Reserved. 4
5 It s a huge opportunity, everyone with a genome B R I N G I N G G E N E T I C S I N T O M A I N S T R E A M M E D I C I N E T O H E L P B I L L I O N S O F P E O P L E Everyone has a unique genome that has a significant impact on their health There are over 4,000 medically important genetic tests today most of which are over-priced and under-utilized High quality, low priced genetic testing will dramatically increase the total market to everyone with access to healthcare Invitae Corporation. All Rights Reserved. 5
6 A genetic information platform built for long term growth Genetic Testing Genome Network Genome Management - Consolidate and expand the market for genetic tests and related services - Accurately diagnose more patients and connect them to therapies earlier - Manage genetic information for customers throughout their lifetime Invitae Corporation. All Rights Reserved. 6
7 Strong Start to 2017 Well positioned to achieve 2017 goals of 110, ,000 samples accessioned and full-year revenue of between $55M and $65M Robust sample volume growth Continued improvement in COGS Steady progress with payers On-track to be cash-flow positive by the end of 2018 Invitae Corporation. All Rights Reserved. 7
8 14 th consecutive quarter of double digit sequential growth Accessioned volume Accessioned over 26K samples Strong year-over-year growth Expanded sales force now in the field Projecting K samples accessioned total in ,500 26,000 Q1:17 15,500 Q4:16 10,000 12,500 Q2:16 Q3:16 Q1:16 Invitae Corporation. All Rights Reserved. 8
9 Our cost structure sets us apart COGS per sample Average cost per sample of ~$360 More than 40% improvement yearover-year 10% improvement quarter-overquarter $ 600 Q1:16 $ 500 Expect to continue lowering COGS throughout 2017 Q2:16 $ 450 Q3:16 $ 400 Q4:16 $ 360 Q1:17 Invitae Corporation. All Rights Reserved. 9
10 A growing business increasing in value Value of billable reports Q1 billable report value of $27.6M $27.6M $22.6M Q1:17 $16.6M Q4:16 $11.8M $11.7M Q3:16 Q1:16 Q2:16 Invitae Corporation. All Rights Reserved. 10
11 Continued progress with payers, increasing access Lives Contracted 187 million lives contracted Operationalizing contracts with major payers 160M 175M 187M Contracting with state Medicaid programs Q4:16 Q1:17 Secured coverage for newly launched boosted exome 95M Q3:16 Q2:16 6M Q1:16 Invitae Corporation. All Rights Reserved. 11
12 Continued double digit sequential revenue growth Revenue $10.3M in Q1 revenue More than 150% year-over-year growth Nearly 12% sequential growth Expect 2017 revenue from $55 65M $9.2M Q4:16 $10.3M Q1:17 $6.3M $5.6M Q3:16 $4.0M Q2:16 Q1:16 Invitae Corporation. All Rights Reserved. 12
13 Best-in-class cost infrastructure sustains gross margin positivity Gross margin positive $15 average gross margin per report during high volume quarter $47 Q4:16 $15 ($74) ($64) Q1:17 Q2:16 Q3:16 ($209) Q1:16 Invitae Corporation. All Rights Reserved. 13
14 Maintaining leverage from operating expenses Volume Q1 operating expenses of $28.3M 26,000 samples $5.6M in non-cash expenses 10,000 samples 12,500 samples 15,500 samples 20,500 samples $23.5M $23.9M $23.9M $26.0M $28.3M OpEx Q1:16 Q2:16 Q3:16 Q4:16 Q1:17 Invitae Corporation. All Rights Reserved. 14
15 Funded to cash flow positive in 2018 Ended Q1 with $101.5M in cash Completed $40M debt financing Volume Cash 26,000 samples Extinguished $12.1M in previously outstanding debt Additional $20M available in ,000 samples $22.0M cash used in operating activities in Q1 as compared to $24.0M in Q Cash flow positive by the end of 2018 $23.5M 0 Cash Cash ($24.0) ($23.1M) OpEx ($16.9) ($17.0M) ($18.4M) ($18.5M) ($18.8M) $28.3M ($22.0M) ($21.2M) Q1:16 Q2:16 Q2:16 Q3:16 Q3:16 Q4:16 Q4:16 Q1:17 Invitae Corporation. All Rights Reserved. 15
16 A platform built for long term growth Genetic Testing Genome Network Genome Management - Consolidate and expand the market for genetic tests and related services - Accurately diagnose more patients and connect them to therapies earlier - Manage genetic information for customers throughout their lifetime Invitae Corporation. All Rights Reserved. 16
17 Genome Network: insights to drive care and innovation A patient-centered data platform optimizing the search for better treatments Permission-based network to collect, curate and share patient and clinician reported health data Identify large populations with demand for genetic information to aid in treatment and biopharma discovery Clinical trial screening, sponsored testing programs, physician/patient identification and outreach Hereditary disease treatment research Disease Education Learn from Other Patients Take Surveys Get Reminders Upload Medical Records Import Clinical Data Adhere to Protocols Get Screened for Clinical Trials
18 Diagnosing more patients correctly, bringing therapies to market faster R E P R E S E N TAT I V E H E R E D I TA R Y D I S E A S E C O M PA N I E S Clinical trial screening Sponsored testing programs Physician/patient identification and outreach Hereditary disease treatment research Invitae Corporation. All Rights Reserved. 18
19 Continued aggregation of the world s genetic tests into a single, high quality, affordable platform Content available Expanded to more than 1,100 genes in production and leap-frogged our 3,000 gene target to prepare 20,000 gene exome >20,000 genes 2017 >200 genes >600 genes >1,000 genes Estimates. Invitae Corporation. All Rights Reserved. 19
20 Exome lays the groundwork for genome management The same comprehensive quality, speed and pricing clients have come to expect from Invitae Moving the market away from figuring out what question to ask to asking a question and getting the answer Invitae Corporation. All Rights Reserved. 20
21 Genetics will inform medicine over the course of a patient s lifetime NEONATAL MEDICAL CONDITION MEDICATIONS HAVING KIDS INJURIES OR SURGERIES HEALTH ISSUES AGING GRACEFULLY Newborn screening Clinical diagnostics PGx screening Carrier testing Bleeding disorders Focused clinical trials Proactive health Genome Management services on behalf of the individual, partnering with Provider networks Payers and governments Family members Advocacy organizations Testing and monitoring partners Biopharmaceutical developers Other Invitae Corporation. All Rights Reserved. 21
22 Simple model disrupting an industry Lower prices Lower costs Expand content Attract Partners Growth Improve customer experience Drive Volume Invitae Corporation. All Rights Reserved. 22
23
JEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE JUNE 3, 2015 NACHUM HOMI SHAMIR PRESIDENT AND CHIEF EXECUTIVE OFFICER
JEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE JUNE 3, 2015 NACHUM HOMI SHAMIR PRESIDENT AND CHIEF EXECUTIVE OFFICER SAFE HARBOR STATEMENT Certain statements made during the course of this presentation may
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationDEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE WHEN COMMERCIALIZING A MEDICINE, IT
More informationSecond Quarter 2016 Financial Results. August 4, 2016
Second Quarter 2016 Financial Results August 4, 2016 Cautionary Note Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain forward-looking
More informationSupplemental Financial Schedules May 19, 2015
Supplemental Financial Schedules May 19, 2015 The presentations and related schedules contain financial measures that are not calculated in accordance with generally accepted accounting principles (GAAP).
More informationHelping make the health system work better for everyone. Solutions for Payers
Helping make the health system work better for everyone. Solutions for Payers Pressing Challenges. Unprecedented Opportunities. A new health care marketplace is taking shape one that presents greater quality,
More informationNew Frontiers in Personalized Medicine
New Frontiers in Personalized Medicine Oracle Open World Shanghai 2013 Neil de Crescenzo SVP and GM 1 Safe Harbor Statement The following is intended to outline our general product direction. It is intended
More informationThe Promise of Data-Driven Healthcare
The Promise of Data-Driven Healthcare MegaTrends for 2018 and Beyond February 27, 2018 Presenters 1 Valerie Barton, Managing Director Valerie oversees Manatt s data and analytics capability. She works
More informationPAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey
PAREXEL GENOMIC MEDICINE SERVICES Applying genomics to enhance your drug development journey YOUR JOURNEY. OUR MISSION. Genomic expertise to simplify the route to product approval and maximize patient
More informationA Leading Global Health Care Group
A Leading Global Health Care Group Frankfurt stock exchange: FRE US ADR program: FSNUY www.fresenius.com/investors General Presentation, Fresenius SE & Co. KGaA, Investor Relations Copyright, August 2016
More informationYASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA.
YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA wns wns ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN
More informationA LEADING GLOBAL HEALTH CARE GROUP. Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY
A LEADING GLOBAL HEALTH CARE GROUP Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY www.fresenius.com/investors SAFE HARBOR STATEMENT This presentation contains forward-looking statements
More informationPharmaceutical Product Development NASDAQ: PPDI. Dan Darazsdi Chief Financial Officer. Credit Suisse Healthcare Conference November 2009
Pharmaceutical Product Development NASDAQ: PPDI Dan Darazsdi Chief Financial Officer Credit Suisse Healthcare Conference 2009 12 November 2009 Safe Harbor Except for historical information, all of the
More informationINVESTOR PRESENTATION. February 2018
INVESTOR PRESENTATION February 2018 Forward Looking Statement Disclaimer This presentation contains statements, including statements about future plans and expectations, which constitute forward-looking
More informationGood day, ladies and gentlemen. Welcome to today s conference call to discuss Stratasys third quarter 2017 financial results.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 SSYS Q3 2017 Earnings Script SLIDE 1 & 2: TITLE SLIDES SPEAKER:
More informationAgios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationTHE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION
THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION William S. Dalton, PhD, MD AACR April 17, 2016 Designing a Federated Model To Support Research & Healthcare Offices
More informationA Leading Global Health Care Group
A Leading Global Health Care Group Roadshow Copenhagen October 6, 2015 For detailed financial information please see our annual/quarterly reports and/or conference call materials on www.fresenius.com/ir.
More informationNHS ENGLAND BOARD PAPER
NHS ENGLAND BOARD PAPER Paper: PB.30.03.2017/06 Title: Creating a genomic medicine service to lay the foundations to deliver personalised interventions and treatments Lead Director: Professor Sir Bruce
More informationSecond Quarter 2015 Earnings Conference Call Prepared Remarks August 5th, 2015
Second Quarter 2015 Earnings Conferen nce Call Prepared Remarks August 5th, 2015 Mark McKechnie: Thank you. Welcome to our second quarter 2015 earnings call. With me on the call today are Scott Lang, our
More informationAddressing attrition in neurosciences. Dr Ismail Kola Head UCB NewMedicines
Addressing attrition in neurosciences Dr Ismail Kola Head UCB NewMedicines Disclaimer and safe harbour Forward-looking statements: This presentation contains forward-looking statements based on current
More informationTRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS
TRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS THE DOORS ARE OPEN: FEEL FREE TO COME IN CENTOGENE UNLOCKS THE POWER OF GENETIC INSIGHTS TO IMPROVE THE QUALITY OF LIFE OF PATIENTS WITH GENETIC
More informationirobot First-Quarter 2017 Conference Call Script
irobot First-Quarter 2017 Conference Call Script Operator: Good day everyone and welcome to the irobot first-quarter 2017 financial results conference call. This call is being recorded. At this time for
More informationTCS Financial Results
TCS Financial Results Quarter III FY 2017-18 Jan 11, 2018 1 Copyright 2017 Tata Consultancy Services Limited Disclaimer Certain statements in this release concerning our future prospects are forward-looking
More informationNPS Pharma Pioneering and delivering innovative therapies that transform the lives of patients with rare diseases worldwide
NPS Pharma Pioneering and delivering innovative therapies that transform the lives of patients with rare diseases worldwide Jefferies 2014 Global Healthcare Conference June 2, 2014 Francois Nader, MD President
More informationLEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS
LEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS SAFE HARBOR STATEMENT This presentation contains forward-looking statements that are based
More informationR1 to Acquire Intermedix and Selected as RCM Services Provider for Ascension Physician Business
R1 to Acquire Intermedix and Selected as RCM Services Provider for Ascension Physician Business Investor Presentation February 26, 2018 Forward-Looking Statements and Non-GAAP Financial Measures This presentation
More informationFuture bound. Philips Ingenuity Core
Future bound Philips Ingenuity Core High reliability Low-dose, high-quality imaging and coverage, and the ability to personalize image quality* patient by patient. Expect excellence in routine imaging,
More informationDevices, Big Data, and Real World Evidence O R A C L E W H I T E P A P E R O C T O B E R
Devices, Big Data, and Real World Evidence O R A C L E W H I T E P A P E R O C T O B E R 2 0 1 7 Disclaimer The following is intended to outline our general product direction. It is intended for information
More information35th Annual J.P. Morgan Healthcare Conference
35th Annual J.P. Morgan Healthcare Conference Investor Presentation Nachum Homi Shamir President and Chief Executive Officer January, 2017 Safe Harbor Statement Certain statements made during the course
More informationIBM Systems Unleashing the power of a software defined infrastructure
IBM Systems Unleashing the power of a software defined infrastructure Learn how organizations in cancer research, speech recognition, financial services, automotive design and more are using IBM solutions
More informationMDM offers healthcare organizations an agile, affordable solution To deliver high quality patient care and better outcomes
MDM offers healthcare organizations an agile, affordable solution To deliver high quality patient care and better outcomes Many healthcare organizations are struggling with rising costs and inconsistent
More informationISPOR 19 th International Meeting May 31 st June 4 th 2014, Montréal International Society for Pharmacoeconomics and Outcomes Research
ISPOR 19 th International Meeting May 31 st June 4 th 2014, Montréal International Society for Pharmacoeconomics and Outcomes Research Pascale Boyer Barresi, CFA Business Analysis, BD&L September 2014
More informationSORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationHow can pharma outsourcing partners overcome the challenges of a rapidly changing industry?
How can pharma outsourcing partners overcome the challenges of a rapidly changing industry? ADAPTING TO CHANGE IN CONTRACT PHARMA How can pharma outsourcing partners overcome the challenges of a rapidly
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2017 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationTechnology and data-driven decisions are driving best practices for patient collections
Technology and data-driven decisions are driving best practices for patient collections New research shows commonalities, opportunities for continued improvement An Experian Health perspective HFMA surveyed
More informationHelping unlock growth opportunities worldwide
Helping unlock growth opportunities worldwide A trusted partner for high-stakes decisions While scientific and technological advances fuel new business opportunities, the cost of bringing each new product
More informationShivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare
Shivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare The world of healthcare is changing - with two revolutionary technologies, genomics and blockchain poised to significantly
More informationThe power of the Converge platform lies in the ability to share data across all aspects of risk management over a secure workspace.
Converge Platform The transition to value-based care is breaking down the barriers between the CNO, CMO, and Chief Legal Counsel in managing enterprise risk. It s time to take a proactive systems approach
More informationCentricity 360 Suite Case Exchange Physician Access Patient Access
Centricity 360 Suite Case Exchange Physician Access Patient Access Unleash the power of GE collaboration solutions to bring your distributed care teams together. Centricity 360 Suite with Case Exchange,
More informationTCS Financial Results
TCS Financial Results Quarter I FY 2017-18 July 13, 2017 1 Copyright 2017 Tata Consultancy Services Limited Disclaimer Certain statements in this release concerning our future prospects are forward-looking
More informationThird Quarter 2009 Results. Analysts and Media Conference November 5, 2009 Zurich
Third Quarter 2009 Results Analysts and Media Conference November 5, 2009 Zurich This presentation contains forward looking statements which involve risks and uncertainties. The actual performance, results
More informationACO and Collaborative Care - Solutions Portfolio. Tools, resources, and expertise for your ACO/Collaborative Care Journey
ACO and Collaborative Care - Solutions Portfolio Tools, resources, and expertise for your ACO/Collaborative Care Journey Accountable Care Begins Here Accountable care and value-based care delivery models
More informationExtending our Reach. Investor Presentation, March 1, 2018
Extending our Reach Investor Presentation, March 1, 2018 Looking Forward Statements The statements in this presentation relating to matters that are not historical fact are forward looking statements that
More informationKonica Minolta to Acquire Ambry Genetics (US)
Konica Minolta to Acquire Ambry Genetics (US) Full-fledged Entry into Precision Medicine July 6, 2017 0 1. Transaction Details and Positioning in KM s Strategy 2. Full-fledged Entry into Precision Medicine
More informationTransformational Data-Driven Solutions for Healthcare
Transformational Data-Driven Solutions for Healthcare Transformational Data-Driven Solutions for Healthcare Today s healthcare providers face increasing pressure to improve operational performance while
More informationQ4 and Full Year 2017 Conference Call. February 22, 2018
Q4 and Full Year 2017 Conference Call February 22, 2018 Agenda Welcome McDavid Stilwell VP, Corporate Communications and Investor Relations Q4 2017 and Full Year Review and Recent Highlights Dr. Sandy
More informationLeveraging Internal Audit and Corporate Compliance for Effective Risk Management
Leveraging Internal Audit and Corporate Compliance for Effective Risk Management April 18, 2016 Don Sinko Chief Integrity Officer Cleveland Clinic Agenda Cleveland Clinic Integrity Office Model The 3 Lines
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationGE Healthcare. Optima NM/CT 640
GE Healthcare Optima NM/CT 640 Great and lasting performance in a SPECT/CT system? Precisely. We invented hybrid SPECT/CT. And now we re perfecting it. Introducing the Optima* NM/CT 640 from GE Healthcare
More informationTOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS
TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS William S. Dalton, PhD, MD CEO, M2Gen & Director, Personalized Medicine Institute, Moffitt Cancer Center JULY 15, 2013 MOFFITT CANCER CENTER
More informationLetter to Shareholders Q2 FY18
November 2, 2017 Letter to Shareholders Q2 FY18 CIRRUS LOGIC, INC. 800 WEST SIXTH STREET, AUSTIN, TEXAS 78701 November 2, 2017 Dear Shareholders, Cirrus Logic reported outstanding results in the September
More informationFINANCIAL PERSPECTIVES
FINANCIAL PERSPECTIVES M³ - Meet Merck Management Marcus Kuhnert, CFO Darmstadt December 10, 2015 Disclaimer Cautionary Note Regarding Forward-Looking Statements This communication may include forward-looking
More information+ 3.1bn bn bn bn. Organic revenue ( m) 8,371 7,820 7,377 7,018 6,627 6,496 5,854 5,275 4,908 4,504 4,111 3,810
Jeremy Darroch This document contains certain forward looking statements with respect to the Group s financial condition, results of operations and business, and our strategy, plans and objectives for
More informationDUCHENNE MUSCULAR DYSTROPHY CLINICAL DEVELOPMENT PROGRAM
DUCHENNE MUSCULAR DYSTROPHY CLINICAL DEVELOPMENT PROGRAM Dana R. Martin, PharmD Sarepta Therapeutics PPMD ANNUAL CONNECT CONFERENCE ORLANDO, FLORIDA JUNE 27, 2016 FORWARD LOOKING STATEMENTS This presentation,
More informationOracle Product Hub Cloud
Oracle Product Hub Pre-Release Draft Subject to Change. Subject to Safe Harbor statement in Footnotes Oracle Product Hub is an enterprise-class product information management system, delivered via for
More informationTecan Group 34 th Annual J.P. Morgan Healthcare Conference DR. DAVID MARTYR, CEO JANUARY 14, 2016 SAN FRANCISCO, USA
Tecan Group 34 th Annual J.P. Morgan Healthcare Conference DR. DAVID MARTYR, CEO JANUARY 14, 2016 SAN FRANCISCO, USA Safe Habor Statement All statements in this presentation not referring to historical
More informationCommunicating Emerging Drug Therapies Prior to FDA Approval. May 4, 2017
Communicating Emerging Drug Therapies Prior to FDA Approval May 4, 2017 Michelle Drozd Deputy Vice President, Policy and Research Pharmaceutical Research Manufacturers Association (PhRMA) Michael Labson
More informationOver a Hundred Reporting Clients throughout the country. 95%+ Client Retention
The Leader in Web-based Reporting for Managed Care Organizations Diverse base of Managed Care clients (IPAs, PHOs, HMOs & MSOs) Providing Managed Care Analytics and Business Intelligence for over 10 years
More informationHealthcare Expertise for Your Business
Healthcare Expertise for Your Business The Premier Bank Serving Healthcare Businesses in Texas Texas Capital Bank specializes in serving the diverse and complex needs of the rapidly changing healthcare
More informationNext Generation Sequencing (NGS) Market Size, Growth and Trends ( )
Next Generation Sequencing (NGS) Market Size, Growth and Trends (2014-2020) July, 2017 4 th edition Information contained in this market report is believed to be reliable at the time of publication. DeciBio
More informationLIFE SCIENCES. Patient Inspired. Outcome driven. JENNIFER DONATELLI KENNETH MUNIE NATASHA SUNDERJI
LIFE SCIENCES Patient Inspired. Outcome driven. JENNIFER DONATELLI KENNETH MUNIE NATASHA SUNDERJI OPENING EMERGING MARKETS TO PROFITABLE GROWTH WITH DIGITAL SUPPLY NETWORKS Nearly 2 billion people have
More informationPERSONALISED MEDICINE FOR THE BENEFIT OF PATIENTS
PERSONALISED MEDICINE FOR THE BENEFIT OF PATIENTS CLEAR DIAGNOSIS TARGETED TREATMENT STRENGTHENED RESEARCH SUMMARY NATIONAL STRATEGY FOR PERSONALISED MEDICINE 2017-2020 FOREWORD Personalised Medicine
More informationA High-Touch Approach to Improving Patient Access. Using field support to navigate reimbursement challenges
A High-Touch Approach to Improving Patient Access Using field support to navigate reimbursement challenges For the brand and reimbursement teams who must develop commercial strategies for the biopharmaceutical
More informationCredit Suisse 10 th Annual Global Services Conference
Credit Suisse 10 th Annual Global Services Conference Lynn Blodgett, President and Chief Executive Officer Kevin Kyser, Chief Financial Officer February 25, 2008 This presentation may contain forward-looking
More informationNew Cardinal Health (Post-Spin)
New Cardinal Health (Post-Spin) George Barrett Vice Chairman and Chief Executive Officer Healthcare Supply Chain Services and Chief Executive Officer Cardinal Health, Inc. (post-spin) January 14, 2009
More informationMeeting the Demands of a Transitioning Market with Oracle Utilities Customer Care and Billing for Integrated Utilities
Meeting the Demands of a Transitioning Market with Oracle Utilities Customer Care and Billing for Integrated Utilities Oracle Utilities has an unrivalled track record in transforming former utility incumbents
More informationQ Presentation , Oslo
Q4 2017 Presentation 01.02.2018, Oslo Agenda Highlights BetaGlucans Animal- and Consumer health Cancer Advanced wound care Enzymes Molecular and new markets Q4 Financials Outlook for 2018 2 Biotec in brief
More informationImpact of Patient Engagement on Project Valuation
Impact of Patient Engagement on Project Valuation Bennett Levitan, MD-PhD Epidemiology, Janssen Research and Development CTTI Patient Groups & Clinical Trials Expert Meeting January 22, 2015 2 Disclosures
More informationWHILE A SMALL NUMBER OF PEOPLE ARE SUFFERING FROM A SINGLE RARE DISEASE, 350 MILLION PEOPLE WORLDWIDE ARE SUFFERING FROM RARE DISEASES.
June 2017 WHILE A SMALL NUMBER OF PEOPLE ARE SUFFERING FROM A SINGLE RARE DISEASE, 350 MILLION PEOPLE WORLDWIDE ARE SUFFERING FROM RARE DISEASES. 3rd most populous country 50% of affected are children
More informationHow Information Transformation Drives Healthcare Performance
perspective How Information Transformation Drives Healthcare Performance Abstract Healthcare delivery in the US is experiencing tectonic change and has rapidly moved towards a Consumer-centric, market-driven
More informationPPACA Shared Responsibility Ensuring Healthcare Reform Compliance
PPACA Shared Responsibility Ensuring Healthcare Reform Compliance Executive Summary As the impact of healthcare reform increases, employers must prepare for their new obligations and responsibilities under
More informationGenomics Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research
Genomics Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research " Increasing usage of novel genomics techniques and tools, evaluation of their benefit to patient outcome and focusing
More informationProject Destiny Summary
Project Destiny Summary The American Pharmacists Association (APhA), the National Association of Chain Drug Stores (NACDS), and the National Community Pharmacists Association (NCPA) have joined together
More informationInvestor Presentation
Investor Presentation September 2009 Safe Harbor Statement With the exception of historical information, this presentation contains forward-looking statements that are made pursuant to the "safe harbor"
More informationPAREXEL STRATEGIC PARTNERSHIPS. Optimizing relationships for shorter time to market
PAREXEL STRATEGIC PARTNERSHIPS Optimizing relationships for shorter time to market YOUR JOURNEY. OUR MISSION. Delivering a more collaborative and operationally efficient relationship so you can reach your
More informationOracle Buys ClearTrial Adds Leading Cloud-based Clinical Trial Operations and Analytics Applications to the Oracle Health Sciences Suite
Oracle Buys ClearTrial Adds Leading Cloud-based Clinical Trial Operations and Analytics Applications to the Oracle Health Sciences Suite April 12, 2012 Oracle is currently reviewing
More informationUBS Media Conference Neil Berkett, Acting CEO 5 December 2007
UBS Media Conference Neil Berkett, Acting CEO 5 December 2007 Forward-looking statements Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Various statements contained in
More informationTHE BIOLOGIC DRUG MARKET. ebook: The current state of biologic drugs and the challenges ahead
THE BIOLOGIC DRUG MARKET 2 0 1 7 HOW DO DRUGS AND BIOLOGICS DIFFER? This ebook answers that question, and so much more. OptumRx has summarized the complex and expensive world of biologic drugs for you.
More informationGrupo Fleury: history, market and strategic positioning, future. Mr. Carlos Marinelli Chief Executive Officer
Grupo Fleury: history, market and strategic positioning, future Mr. Carlos Marinelli Chief Executive Officer Grupo Fleury in numbers: purpose 90 years and reference healthcare company in Brazil 145 PSCs
More informationChina Nepstar Chain Drugstore Ltd.
China Nepstar Chain Drugstore Ltd. NYSE:NPD Presentation to Investors November 2012 HK000NM6_Eng Safe Harbor This presentation contains forward-looking statements. These statements constitute forward-looking
More informationFacts & Figures: The Present and Future of ICN. Thomas Ganswindt, Group President Michael Kutschenreuter, Chief Financial Officer
Facts & Figures: The Present and Future of ICN Thomas Ganswindt, Group President Michael Kutschenreuter, Chief Financial Officer Financial Market Days, May 13, 2003 Cleaning house Clean up Rebuild Harvest
More informationPhysician Office Billing & Payment Guide
Physician Office Billing & Payment Guide Dermal Regeneration Matrix Dermal Repair Scaffold Ag Antimicrobial Dermal Repair Scaffold Physician Office Billing & Payment Guide Billing and Medicare Payment
More informationSpark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationInvestor Presentation. June 2015
Investor Presentation June 2015 Important Information for Investors and Shareholders This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities
More informationQIAGEN - Financials. Roland Sackers Chief Financial Officer. Sample & Assay Technologies -1- QIAGEN Analyst and Investor Day, February 14, 2008
QIAGEN - Financials -1- Roland Sackers Chief Financial Officer Forward Looking Statements Safe Harbor Statement: Certain of the statements contained in this presentation may be considered forward-looking
More informationReimagining Life Sciences With AI-Enabled Digital Transformation. Abstract
Reimagining Life Sciences With AI-Enabled Digital Transformation Abstract Technological, regulatory and environmental changes, along with an increasingly active involvement of patients in their treatment
More informationReporting Results and Incidental Findings to Research Participants
Reporting Results and Incidental Findings to Research Participants Jeffrey R Botkin, MD, MPH Professor of Pediatrics Chief, Division of Medical Ethics and Humanities Associate Vice President for Research
More informationORACLE FINANCIAL ANALYTICS
ORACLE FINANCIAL ANALYTICS KEY FEATURES AND BENEFITS FOR BUSINESS USERS Receive intraperiod information on income statement, cash flow, and balance sheet condition without having to perform consolidations
More informationPROFIT POOLS, DEFINED.
Matthew Collier PROFIT POOLS, DEFINED. Capital allocation solely on the basis of smart money or potential market segment size is sub-optimal. Instead, profit pool analysis presents a wiser and more comprehensive
More informationThe Growth Strategy of Shionogi. September, 2011
The Growth Strategy of Shionogi September, 2011 Forward-Looking Statements This presentation contains forward-looking statements. These statements are based on expectations in light of the information
More informationTransform Payables into Strategic Assets
SAP Brief SAP Ariba Financial Supply Chain SAP Ariba Payables Transform Payables into Strategic Assets SAP Brief Time your payments to improve your company s balance sheet Your ability to time payments
More informationStrategic Plan. Uniting to care & cure
2017-2019 Strategic Plan Uniting to care & cure Table of Contents Message from the President & CEO Page 2 Overview Page 3 Mission Page 4 Core Values Page 5 2017-2019 Objectives & Strategies Page 6 Mission
More informationBridging the Gap in Precision Medicine An Informatics Solution Connecting Research, Pathology, and Clinical Care
Bridging the Gap in Precision Medicine An Informatics Solution Connecting Research, Pathology, and Clinical Care O R A C L E W H I T E P A P E R F E B R U A R Y 2 0 1 6 Disclaimer The following is intended
More informationBioPharm. Smart Outsourcing: Strategic Alignment, Risk Management, and New Relationships
BioPharm Volume 25 Number 3 INTERNATIONAL March 2012 The Science & Business of Biopharmaceuticals Smart Outsourcing: Strategic Alignment, Risk Management, and New Relationships Outsourcing decisions should
More informationAnnual General Meeting Roche Holding Ltd 6 March 2012
r Annual General Meeting Roche Holding Ltd 6 March 2012 Address by Franz B. Humer Chairman of the Board of Directors (Check against delivery.) Address by Franz B. Humer Page 2/12 Dear Shareholders, Ladies
More informationeplus Vendor FINANCING Increase Sales Opportunities and Grow Your Business
eplus Vendor FINANCING Increase Sales Opportunities and Grow Your Business By leveraging the experience, success, and financial strength of eplus, our OEM partners and other solution providers benefit
More information